Skip to Main Content

Author Details

Antonio Hurtado-Coll
University of British Columbia
2002
53
29
PMIDPaper TitleJournal TitlePublished Year
37343766Artificial Intelligence-Based PTEN Loss Assessment as an Early Predictor of Prostate Cancer Metastasis After Surgery: A Multicenter Retrospective Study.Mod Pathol2023
35145197Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25â¿¿mm diameter as an optimal definition for "large" cribriform prostatic adenocarcinoma.Mod Pathol2022
33418978Steroidogenesis in Peripheral and Transition Zones of Human Prostate Cancer Tissue.Int J Mol Sci2021
33420073Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer.Nat Commun2021
32793395A simple method for detecting oncofetal chondroitin sulfate glycosaminoglycans in bladder cancer urine.Cell Death Discov2020
32041631Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.J Exp Clin Cancer Res2020
30638634Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.Eur Urol2019
29334632Capillary electrophoresis-mass spectrometry for targeted and untargeted analysis of the sub-5⿯kDa urine metabolome of patients with prostate or bladder cancer: A feasibility study.J Chromatogr B Analyt Technol Biomed Life Sci2018
30241348Characterization of Precursor-Dependent Steroidogenesis in Human Prostate Cancer Models.Cancers (Basel)2018
30015382Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma.J Pathol2018
29464091Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer.Oncotarget2018
27358489Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer.Clin Cancer Res2017
27756786A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.Clin Cancer Res2017
27136741Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies.Prostate Cancer Prostatic Dis2016
27617307PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer.Eur Urol Focus2016
27846218MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study.PLoS One2016
27635949Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort.Am J Surg Pathol2016
27174589Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.Mod Pathol2016
27325561Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort.Prostate2016
25544761Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer.Oncotarget2015
26172920Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.PLoS One2015
25939393A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.Prostate2015
24356420High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development.Cancer Res2014
25217961A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.Nat Genet2014
25046620DHH is an independent prognosticator of oncologic outcome of clear cell renal cell carcinoma.J Urol2014
25155515Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer.Genome Biol2014
24839475Comparison of open and robotic-assisted prostatectomy: The University of British Columbia experience.Can Urol Assoc J2014
24664419Prostate stromal cells express the progesterone receptor to control cancer cell mobility.PLoS One2014
22277631Salvage prostatectomy post-definitive radiation therapy: The Vancouver experience.Can Urol Assoc J2013
23232570A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray.Adv Anat Pathol2013
23334893Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause-specific mortality.Prostate2013
22887727Investigation of the relationship between prostate cancer and MSMB and NCOA4 genetic variants and protein expression.Hum Mutat2013
22294438Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer.J Pathol2012
22481061A novel oral dosage formulation of the ginsenoside aglycone protopanaxadiol exhibits therapeutic activity against a hormone-insensitive model of prostate cancer.Anticancer Drugs2012
22553170From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer.J Pathol2012
22252602Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target.Mol Cancer Ther2012
21420229Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration.Eur Urol2011
21388585Radical prostatectomy for high-risk clinically localized prostate cancer: a prospective single institution series.Can Urol Assoc J2011
21443656Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence.BJU Int2011
20503398Relaxin drives Wnt signaling through upregulation of PCDHY in prostate cancer.Prostate2010
19301006Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy.Cancer Chemother Pharmacol2009
18336596Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.BJU Int2008
18694509Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer.BMC Cancer2008
16997353Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.Hum Pathol2007
17259299Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.J Clin Pathol2007
15770516Mechanisms of the development of androgen independence in prostate cancer.World J Urol2005
15374973Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.Cancer Res2004
15574769Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model.Cancer Res2004
15776859[Efficacy and safety of vardenafil in patients with erectile dysfunction. Results of the Mexican Multicentric Study].Rev Invest Clin2004
14586548Androgens and prostate cancer.World J Urol2003
  • 1 - 50 of 53

Recommended Authors

Michael C Haffner
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 24
Mitchell G Lawrence
Biomedicine Discovery Institute, Monash University
Career Start Year 2005
Number of shared co-authors 7
Gerhardt Attard
The Institute of Cancer Research
Career Start Year 2004
Number of shared co-authors 33
Thorsten Schlomm
Charite - University Hospital Berlin
Career Start Year 2004
Number of shared co-authors 15
Channing J Paller
Johns Hopkins University School of Medicine
Career Start Year 2004
Number of shared co-authors 10
Ashley E Ross
Northwestern University
Career Start Year 2003
Number of shared co-authors 37
Tarek A Bismar
University of Calgary Cumming School of Medicine, Rockyview General Hospital
Career Start Year 2002
Number of shared co-authors 29
Mark C Markowski
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2001
Number of shared co-authors 6
Ilsa Coleman
Fred Hutchinson Cancer Center
Career Start Year 2001
Number of shared co-authors 27
Eleni Efstathiou
Houston Methodist Cancer Center
Career Start Year 2000
Number of shared co-authors 20
Jiaoti Huang
Duke University School of Medicine
Career Start Year 2000
Number of shared co-authors 23
Emmanuel S Antonarakis
The Sidney Kimmel Cancer Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2000
Number of shared co-authors 21
Tomasz M Beer
OHSU Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2000
Number of shared co-authors 32
Hayley C Whitaker
University College London
Career Start Year 1999
Number of shared co-authors 16
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 29
Phillip G Febbo
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 19
Eva Corey
University of Washington School of Medicine
Career Start Year 1996
Number of shared co-authors 23
Ganesh V Raj
University of Texas Southwestern Medical Center at Dallas
Career Start Year 1994
Number of shared co-authors 19
Rosina T Lis
National Cancer Institute
Career Start Year 1992
Number of shared co-authors 23
Marshall Scott Lucia
University of Colorado School of Medicine
Career Start Year 1991
Number of shared co-authors 12
Fred Saad
University of Montreal Health Center
Career Start Year 1990
Number of shared co-authors 39
Bruce Montgomery
Fred Hutchinson Cancer Center, University of Washington
Career Start Year 1990
Number of shared co-authors 21
Christopher P Evans
University of California Davis
Career Start Year 1988
Number of shared co-authors 36
Anders Bjartell
Skane University Hospital, Lund University
Career Start Year 1987
Number of shared co-authors 31
Armen Aprikian
McGill University Health Centre, McGill University
Career Start Year 1987
Number of shared co-authors 21
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 34
Oliver Sartor
Tulane University School of Medicine
Career Start Year 1983
Number of shared co-authors 37
Kenneth J Pienta
The Brady Urological Institute, Johns Hopkins University School of Medicine
Career Start Year 1981
Number of shared co-authors 29
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Career Start Year 1981
Number of shared co-authors 44
Howard I Scher
Memorial Sloan Kettering Cancer Center
Career Start Year 1973
Number of shared co-authors 28

Collaborators

Martin E Gleave
University of British Columbia
Co-authored papers 39
Ladan Fazli
University of British Columbia
Co-authored papers 32
Dean A Troyer
Eastern Virginia Medical School
Co-authored papers 13
Peter S Nelson
Fred Hutchinson Cancer Center
Co-authored papers 13
Daniel W Lin
Co-authored papers 13
Lawrence D True
University of Washington School of Medicine
Co-authored papers 12
Ian M Thompson
CHRISTUS Santa Rosa Hospital-Medical Center
Co-authored papers 12
Robert H Bell
University of British Columbia
Co-authored papers 9
Alexander W Wyatt
University of British Columbia
Co-authored papers 8
Raymond S Lance
Washington State University Elson S. Floyd College of Medicine
Co-authored papers 7
Sonal Brahmbhatt
University of British Columbia
Co-authored papers 6
Anne Haegert
University of British Columbia
Co-authored papers 6
Colin C Collins
University of British Columbia
Co-authored papers 6
Yuzhuo Wang
University of British Columbia
Co-authored papers 5
Shawn Anderson
University of British Columbia
Co-authored papers 5
Stanislav V Volik
University of British Columbia
Co-authored papers 5
Janet L Stanford
Fred Hutchinson Cancer Research Center
Co-authored papers 4
Estelle Li
University of British Columbia
Co-authored papers 4
Arul M Chinnaiyan
University of Michigan Medical School.
Co-authored papers 4
Himisha Beltran
Dana-Farber Cancer Institute
Co-authored papers 4
Fan Mo
Institute of Stem Cell and Regeneration, Chinese Academy of Sciences
Co-authored papers 4
Anna Lapuk
Contextual Genomics Inc.
Co-authored papers 4
Chunxiao Wu
Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University
Co-authored papers 3
Mark A Rubin
University of Bern
Co-authored papers 3
Marco A Marra
University of British Columbia
Co-authored papers 3
Jeremy A Squire
University of Sao Paulo
Co-authored papers 3
Kim N Chi
University of British Columbia
Co-authored papers 3
Hui Xue
Agricultural Genomics Institute at Shenzhen, Chinese Academy of Agricultural Sciences
Co-authored papers 3
Robert Shukin
University of British Columbia
Co-authored papers 3
Suzanne Kolb
Fred Hutchinson Cancer Research Center
Co-authored papers 3
Release 1.2